Surgery (Austin & Northern Health) - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/187

Filters

2020 - 2021 2
2
Reset filters

Settings
Statistics
Citations
Start date: 2020 × End date: 2022 × Author: Cox, Daniel × Author: Dobrovic, Alexander ×

Search Results

Now showing 1 - 2 of 2
  • Item
    Thumbnail Image
    Donor-specific cell-free DNA as a biomarker in liver transplantation: A review.
    McClure, T ; Goh, SK ; Cox, D ; Muralidharan, V ; Dobrovic, A ; Testro, AG (Baishideng Publishing Group Inc., 2020-11-28)
    Due to advances in modern medicine, liver transplantation has revolutionised the prognosis of many previously incurable liver diseases. This progress has largely been due to advances in immunosuppressant therapy. However, despite the judicious use of immunosuppression, many liver transplant recipients still experience complications such as rejection, which necessitates diagnosis via invasive liver biopsy. There is a clear need for novel, minimally-invasive tests to optimise immunosuppression and improve patient outcomes. An emerging biomarker in this ''precision medicine'' liver transplantation field is that of donor-specific cell free DNA. In this review, we detail the background and methods of detecting this biomarker, examine its utility in liver transplantation and discuss future research directions that may be most impactful.
  • Item
    Thumbnail Image
    Elevated levels of circulating mitochondrial DNA predict early allograft dysfunction in patients following liver transplantation
    Yoshino, O ; Wong, BKL ; Cox, DRA ; Lee, E ; Hepworth, G ; Christophi, C ; Jones, R ; Dobrovic, A ; Muralidharan, V ; Perini, M (WILEY, 2021-12)
    BACKGROUND AND AIM: The role of circulating mitochondrial DNA (cmtDNA) in transplantation remains to be elucidated. cmtDNA may be released into the circulation as a consequence of liver injury; yet recent work also suggests a causative role for cmtDNA leading to hepatocellular injury. We hypothesized that elevated cmtDNA would be associated with adverse events after liver transplantation (LT) and conducted an observational cohort study. METHODS: Twenty-one patients were enrolled prospectively prior to LT. RESULTS: Postoperative complications were observed in 47.6% (n = 10). Seven patients (33.3%) had early allograft dysfunction (EAD), and six patients (28.5%) experienced acute cellular rejection within 6 months of LT. cmtDNA levels were significantly elevated in all recipients after LT compared with healthy controls and preoperative samples (1 361 937 copies/mL [IQR 586 781-3 399 687] after LT; 545 531 copies/mL [IQR 238 562-1 381 015] before LT; and 194 562 copies/mL [IQR 182 359-231 515] in healthy controls) and returned to normal levels by 5 days after transplantation. cmtDNA levels were particularly elevated in those who developed EAD in the early postoperative period (P < 0.001). In all patients, there was initially a strong overall positive correlation between cmtDNA and plasma hepatocellular enzyme levels (P < 0.05). However, the patients with EAD demonstrated a second peak in cmtDNA at postoperative day 7, which did not correlate with liver function tests. CONCLUSIONS: The early release of plasma cmtDNA is strongly associated with hepatocellular damage; however, the late surge in cmtDNA in patients with EAD appeared to be independent of hepatocellular injury as measured by conventional tests.